Mesoblast stock fell 4.29 percent as Ryoncil controls advanced

Published on 10/07/2026 at 00:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mesoblast stock generated USD 120.3 million in fiscal 2026 revenue, up from USD 17.2 million. FDA approval on September 24, 2026, added a potency test for Ryoncil batches.

MESO, AU000000MSB8, Illustration mit AI erstellt.

Mesoblast stock (ISIN AU000000MSB8) was last at USD 13.61 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 4.29 percent for the session. The company is converting its first commercial product into a broader growth platform while investors weigh execution risk.

Ryoncil quality controls advance

According to GlobeNewswire on September 24, 2026, the FDA approved Mesoblast's T-cell Proliferation Inhibition BioAssay, or TIBA, for release and stability monitoring of every new commercial Ryoncil lot.

The assay will operate alongside existing tests for IL-2Ralpha inhibition and cell adhesion and proliferation. That is a manufacturing and quality milestone rather than a new patient indication, but it matters as Mesoblast scales a therapy already approved for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older.

Revenue reaches USD 120.3 million

GlobeNewswire reported fiscal 2026 results for the year ended June 30, 2026, showing total revenue of USD 120.3 million versus USD 17.2 million in fiscal 2025. Ryoncil generated USD 115.2 million of net product revenue in the same fiscal year.

The commercial progress came with a reduced but still material loss. Mesoblast reported a fiscal 2026 net loss of USD 57.5 million, down from USD 102.1 million in fiscal 2025, while operating cash outflow was USD 43.8 million.

Analysts see USD 39 target

According to MarketBeat on October 2, 2026, two analysts rated Mesoblast Buy and one rated it Sell, producing a Hold consensus and a USD 39.00 average price target. The target lies 186.6 percent above the USD 13.61 Nasdaq price.

The same report placed the 50-day moving average at USD 15.85, above the October 6 price. This gap makes the commercial rollout and the next clinical milestones more important than the assay approval alone.

Nasdaq quote falls 4.29 percent

Mesoblast stock was last at USD 13.61 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, with volume of 403,817 shares and a market capitalization of USD 1.8 billion. The 52-week range was USD 13.05 to USD 21.50.